Dawn Svoronos is Director at Global Blood Therapeutics, Inc. (GBT). They have made 16 open-market trades across 6 companies since 2015, most recently 2026-06-01.
5 open-market purchases totalling $974K since 2017, against 11 sales. Across 5 scored buys the stock is up 7.8% at ninety days, and 1.6 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 60% | 60% | 60% |
| Avg Move | +2.9% | -1.4% | +7.8% |
| Alpha | +1.2% | -2.4% | +1.6% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| XENE | SELL | 2023-08-24 | 2023-08-24 | $38.70 | $1.9M | +2.3% | -7.6% | -24.8% |
| SLRN | BUY | 2023-05-09 | 2023-05-11 | $18.00 | $270K | -15.1% | -25.3% | +1.3% |
| GBT | SELL | 2022-06-21 | 2022-06-22 | $27.24 | $104K | +15.3% | +16.6% | +135.2% |
| PTCT | SELL | 2022-06-09 | 2022-06-10 | $27.20 | $20K | +52.5% | +65.1% | +104.7% |
| ADVM | BUY | 2022-05-16 | 2022-05-18 | $0.85 | $26K | +4.9% | +17.0% | +63.7% |
| PTCT | SELL | 2022-01-07 | 2022-01-11 | $38.53 | $20K | +0.3% | +9.8% | +6.8% |
| GBT | SELL | 2021-06-18 | 2021-06-21 | $36.54 | $118K | +2.5% | -16.2% | -25.6% |
| PTCT | SELL | 2021-06-09 | 2021-06-11 | $41.89 | $15K | +1.3% | +1.5% | -0.8% |
| ADVM | BUY | 2021-03-31 | 2021-04-01 | $10.02 | $200K | -12.4% | -64.5% | -66.6% |
| PTCT | SELL | 2021-02-01 | 2021-02-02 | $56.96 | $29K | +2.5% | -3.5% | -32.0% |
| GBT | SELL | 2020-06-19 | 2020-06-19 | $63.94 | $325K | +4.3% | +9.9% | -19.0% |
| PTCT | SELL | 2020-06-11 | 2020-06-12 | $48.36 | $18K | +8.8% | +9.2% | -4.3% |
| XENE | BUY | 2017-08-14 | 2017-08-15 | $2.82 | $141K | +26.0% | +24.0% | -7.0% |
| PTCT | BUY | 2017-05-23 | 2017-05-24 | $13.49 | $337K | +10.9% | +41.7% | +47.5% |
| MDVN | SELL | 2016-03-14 | 2016-03-16 | $38.90 | $233K | +5.4% | +39.2% | +63.4% |
| MDVN | SELL · 10b5-1 | 2015-09-08 | 2015-09-08 | $89.15 | $276K | -21.1% | +1.2% | +1.2% |
| MDVN | SELL | 2015-03-02 | 2015-03-04 | $119.75 | $401K | -21.1% | +1.2% | +1.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| Total |
| $5.1M |
Shares reported on the most recent Form 4, priced at the 2026-06-03 close.